Search

for
Search:

Research

5 / 138 results

3P's of Valproate: Pharmacokinetic, Pharmacodynamic, and Pharmacogenomic Updates

research 3P's (Pharmacokinetic, Pharmacodynamic, and Pharmacogenomic) of Valproate: What's New?

June 2023 in “International Journal of Pharmaceuticals Nutraceuticals and Cosmetic Science”

New information shows Valproate may protect the brain and reduce breathing failure risk but can cause liver damage and other side effects, with genetics affecting dosage needs.

research The efficacy and safety of valproic acid medications with controlled active ingredient release in adults in real clinical practice from the position of pharmacokinetic and pharmacogenetic approaches

5 citations , January 2017 in “Nevrologiâ, nejropsihiatriâ, psihosomatika”

Sustained-release sodium valproate is effective in treating epilepsy, with some side effects influenced by genetics.

The Role of Candidate Pharmacogenetic Variants in Determining Valproic Acid Efficacy, Toxicity, and Concentrations in Patients with Epilepsy

research The role of candidate pharmacogenetic variants in determining valproic acid efficacy, toxicity and concentrations in patients with epilepsy

October 2024 in “Frontiers in Pharmacology”

Genetic variants can affect valproic acid's effectiveness, side effects, and levels in epilepsy treatment.

research Drugs affecting blood coagulation, fibrinolysis, and hemostasis

January 2009 in “Side effects of drugs annual”

Some blood-thinning medications can increase the risk of bleeding, and certain factors like genetics and other health conditions affect their safety and effectiveness.